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ReviewPhosphoinositide Signaling:
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[9], in cell adhesion, polarization and migration [10, 11],
in remodeling of the actin cytoskeleton [12], and in mito-
genesis and oncogenesis [4, 13]. Activation of cellular
signaling pathways occurs in response to spatially and
temporally regulated production of particular PIPns in
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Echelon Biosciences, Inc. response to a stimulus. As outlined in Figure 2, a given
PIPn then recruits an assemblage of proteins, commonly675 Arapeen Way, Suite 302
Salt Lake City, Utah 84108 referred to as a signalosome, to a given subcellular loca-
tion to modulate a given signaling pathway [14–16]. The
potential implications of modulation of the PI 3-K signal-
ing pathway in developing new therapeutics will be a
Lipid signaling by phosphoinositides (PIPns) involves pervasive subtheme in this review.
an array of proteins with lipid recognition, kinase,
For example, phosphatidylinositol 4,5-bisphosphate,
phosphatase, and phospholipase functions. Under-
or PI(4,5)P2, plays a central role in many cellular functionsstanding PIPn pathway signaling requires identifica- [6]. First, PI(4,5)P2 is a substrate for phospholipase Ction and characterization of PIPn-interacting proteins. (PLC), and some isoforms contain pleckstrin homology
Moreover, spatiotemporal localization and physiologi-
(PH) domains that also bind to PI(4,5)P2 [17]. Hydrolysiscal function of PIPn-protein complexes must be eluci- of the phosphodiester linkage releases the calcium-
dated in cellular and organismal contexts. For protein
mobilizing second messenger Ins(1,4,5)P3. Second,discovery to functional elucidation, reporter-linked
PI(4,5)P2 itself recruits PH domain-containing proteinsphosphoinositides or tethered PIPns have been essen- to membranes; PH domains occur in over 120 human
tial. The phosphoinositide 3-kinase (PI 3-K) signaling
proteins, and each exhibits distinctive PIPn binding affin-pathway has recently emerged as an important source
ities and selectivities [16, 18]. Among these, the most
of potential “druggable” therapeutic targets in human
well-known example is the specific binding of PI(4,5)P2pathophysiology in both academic and pharmaceuti-
to the PH domain of the 1 isoform of PLC [19]. Third,cal environments. This review summarizes the chem-
PI(4,5)P2 binds to non-PH domain-containing proteins,istry of PIPn affinity probes and their use in identifying e.g., gelsolin and profilin, and regulates actin polymer-
macromolecular targets. The process of target valida-
ization [12]. PI(4,5)P2 binding also modulates the GTPasetion will be described, i.e., the use of tethered PIPns activity of adenosine ribosylation factor (Arf) and the
in determining PIPn selectivity in vitro and in establish- phospholipase activity of phospholipase D (PLD) [20,
ing the function of PIPn-protein complexes in living 21], recruits the human class II phosphoinositide
cells.
3-kinase (PI 3-K) to membranes via its C2- PX domain
[22], binds PDZ domains in multiprotein complexes [23],
and binds to the AP180 ENTH domain to mediate endo-
Introduction to Phosphoinositide Signaling cytosis via clathrin-coated pits [24]. The vanilloid recep-
Phosphoinositide (PIPn) signaling networks are dynami- tors and calcium channels in neuronal membranes are
cally modulated by proteins with lipid recognition, kinase, also regulated by the binding or hydrolysis of PI(4,5)P2phosphatase, and phospholipase activities. Lipid-pro- [25, 26]. Finally, PI(4,5)P2 can be converted by PI 3-K totein interactions form the cornerstone for many signaling PI(3,4,5)P3, which activates multiple downstream signal-pathways, and the new discipline of functional lipido- ing events via interactions with numerous PH domains
mics is defining many new targets for therapeutic inter- [4, 27], including the specific protein kinases PDK1 [28,
vention [1]. As illustrated in Figures 1A and 1B, PIPns 29] and Akt [30].
are biosynthesized and interconverted within cells by In addition to PH and ENTH domains, the PI(3)P-spe-
the interplay of kinases [2] and phosphatases [3]. While cific FYVE domains [15, 31] and phox homology (PX)
the parent lipid phosphatidylinositol (PI) lacks additional domains [32–36] target proteins to intracellular mem-
phosphorylation on the inositol ring, the other seven branes. In addition to interactions with membranes, the
known PIPns consist of three monophosphates, three InsPns, and PIPns are part of a nuclear inositide pathway
bisphosphates, and one trisphosphate (Figure 1C). [37, 38], in which PIPns and InsPns regulate chromatin
These charged lipids, particularly the 3-phosphorylated remodeling [39, 40] and reverse inhibition of RNA tran-
lipids [4], are minor components of cellular membranes scription by histones [41], assemble SWI-SNF-like BAF
but are vital as second messengers for diverse cellular complexes [42], and regulate pre-mRNA splicing in nu-
functions [5]. PIPns are essential elements in tyrosine clear speckles [43, 44].
kinase growth factor receptor and G protein receptor Disruption of PI signaling is common to many disease
signaling pathways [6, 7]. Furthermore, these lipid sig- states, including diabetes, cardiovascular disease, and
nals have important roles in membrane trafficking and cancer [45]. Because the activity of PI second messen-
endosome dynamics [8], including endocytosis, exo- gers is determined by their phosphorylation status, the
cytosis, Golgi vesicle movement, and protein trafficking enzymes that act to modify these lipids are central to
the correct execution of these signaling events [46]. For
example, normal cellular levels of PI(3,4,5)P3 are very*Correspondence: glenn.prestwich@hsc.utah.edu
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Figure 1. Chemistry of Phosphoinositide Metabolism
(A) PI 3-K reaction.
(B) Interconversions of PIPns by lipid kinases (red) and lipid phosphatases (green). Enzyme abbreviations are defined in the text.
(C) Structures of the phosphatidylinositol polyphosphates and synthetic analogs.
low, but rise dramatically following growth factor stimu- ing pathway has emerged as the target for development
of a variety of new signal transduction modifying thera-lation. Tyrosine kinase receptors activate class I PI 3-Ks
to catalyze the formation of PI(3,4,5)P3 via phosphoryla- peutic agents [54, 55], such as targeting Akt with small
molecule inhibitors [56].tion of PI(4,5)P2 [4]. By increasing cellular levels of
PI(3,4,5)P3, PI 3-K induces the formation of defined mo- In cancer cells, the activity of PI 3-K and the regulation
of PI(3,4,5)P3 levels is often defective [57, 58]. Elevatedlecular complexes that act in signal transduction path-
ways. Most notably, PI 3-K activity suppresses apopto- PI(3,4,5)P3 levels appear to contribute to cancer progres-
sion in part through constitutive activation of PKB/Aktsis and promotes cell survival through activation of its
downstream target, PKB/Akt [30]. PI(3,4,5)P3-regulated [59], promoting cell survival following detachment from
the extracellular matrix [30]. Increased PI(3,4,5)P3 levelssignaling is governed both by its formation by PI 3-K and
by its conversion into phosphoinositide bisphosphates, are observed in cancer, and cellular transformation is
PI 3-K dependent [60]. Elevated levels of PI(3,4,5)P3 cansuch as PI(4,5)P2 or PI(3,4)P2. An interplay between
PI(3,4,5)P3 formation by PI 3-K and its removal by the occur through amplification of PI 3-K gene expression
[61] or through alterations in the activity of the PIPn3-phosphatase PTEN (phosphatase and tensin homolog
deleted on chromosome 10) controls eukaryotic cell po- phosphatases PTEN or SHIP (SH2-containing inositol
phosphatase), which modulate PI(3,4,5)P3 levels by con-larization and movement [11]. Moreover, PI 3-K is a
critical regulator of immune function [47, 48], particularly verting PI(3,4,5)P3 to PI(4,5)P2 or PI(3,4)P2 respectively,
with concomitant sensitization to chemotherapeuticin T cell activation and mast cell function. Control of PI
3-K and PI(3,4,5)P3 levels have emerged as important drugs [62].
PTEN, a PIPn 3-phosphatase [63] that convertstargets in cardiovascular disease and cancer [49, 50]
as well as allergy and autoimmune disease [51] and PI(3,4,5)P3 to PI(4,5)P2, negatively regulates PKB/Akt ac-
tivation by PI 3-K [64]. The structure of a PTEN-Ins-diabetes, inspiring efforts to design novel isoform-selec-
tive inhibitors [52] and to use PI 3-K inhibitors in a chemi- (1,3,4,5)P4 complex has been solved [65]. Loss of PTEN
activity results in accumulation of PI(3,4,5)P3 [66], abnor-cal genomics approach to elucidate interconnected
pathways in the proteome [53]. In sum, the PI 3-K signal- mal activation of PKB/Akt, suppression of apoptosis
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Figure 2. The PI 3-K/Akt Signaling Pathway and Potential Drug Targets for Cancer Therapy
Additional details on therapeutic targets are provided in several reviews [49–51, 55].
[67], and increased tumorigenesis in a number of human uting factor to the insulin resistance associated with
NIDDM and obesity. Moreover, SHIP2—as with PItissues. PTEN may be a candidate for targeted chemo-
therapy, as anticancer agents can preferentially destroy 3-K—is also a crucial regulator of immune function
[79, 80].tumors with PTEN mutations [58]. Very recently, another
protein tyrosine phosphatase, PTPRQ [68], was shown In order to identify and characterize proteins impor-
tant in the biology described above, chemical affinityto have dual PI(3,4,5)P3 3- and 5-phosphatase activity
that regulates cell survival and proliferation. In addition, probes were developed. The first section below will re-
view the chemistries developed for preparing tetheredthe 3-phosphatase myotubularin (MTM, MTMR) family [69]
has been identified as important PIPn phosphatases that InsPn and PIPn ligands that display reporter groups with
different molecular topologies. The second section willcontribute to lipid remodeling and are commonly mu-
tated in genetic diseases [70]. Moreover, PTEN, Mdm2, provide examples of the use of tethered PIPns for isola-
tion of PIPn binding proteins. The third section will thenand p53 are functionally interrelated, with PTEN acting
as a negative regulator of an oncoprotein-tumor sup- illustrate specific applications for fluorescent, photoaf-
finity, biotinylated, spin-labeled, and resin-immobilizedpressor network to downregulate p53, and p53 acting
to upregulate PTEN production [71]. probes for the characterization of the InsPn and PIPn
binding sites using in vitro biochemical and biophysicalBoth PI 3-K and PTEN are involved in glucose homeo-
stasis and tissue responsiveness to insulin [72]. Defects studies. The fourth and final section will highlight the
uses of tethered PIPns for drug discovery and will brieflyin PI 3-K response to insulin stimulation are associated
with non-insulin-dependent diabetes mellitus (NIDDM), summarize the steps that will be involved in target vali-
dation in cell and organismal biology.or “type II” diabetes. Inhibition of PI 3-K blocks insulin-
stimulated glucose uptake as well as GLUT4 vesicle
translocation [73]. Furthermore, mice deficient in PKB/ Chemistry of PIPn Affinity Reagents
Different molecular topologies have been devised toAkt, which is activated by PI(3,4,5)P3 generated in re-
sponse to insulin, exhibit a diabetes-like phenotype [74]. bind proteins with different active site architectural fea-
tures. The molecular recognition and targeting of lipidAs expected, PTEN also plays a role in control of insulin
sensitivity by attenuating PI(3,4,5)P3 levels in cells. Inhi- binding domains such as the C2, PH, PX, FYVE, PHD,
ENTH, gelsolin, profilin, PI kinase, and PIP phosphatasebition of PTEN activity stimulated GLUT4-mediated glu-
cose transport and increased sensitivity to insulin in vitro domains have been thoroughly reviewed [16, 81]. From
the variety of structures, it is now clear (which it was[75]. Modulation of PI(3,4,5)P3 levels by maintaining con-
trol of PI 3-K and PTEN activities is crucial for glucose not when the first affinity probes were developed) that
the location of the tether, the nature of the linker, andhomeostasis and regulating sensitivity to insulin in
NIDDM. the mimicry of the diacylglyceryl (DAG) moiety needed
to be varied in a given ligand to target and captureThe PIPn 5-phosphatase SHIP2 [76], which converts
PI(3,4,5)P3 to PI(3,4)P2, is also involved in insulin signal- different proteins. A fishing analogy is relevant: different
baits catch different fish. Moreover, a given bait, whiching and diabetes [77]. Homozygous deletion of SHIP2
in mice is fatal due to increased insulin sensitivity and cannot be optimal for all fish, will catch omnivorous
prey as well as highly selective feeders. The differentsevere hypoglycemia; animals heterozygous for the
SHIP2 deletion exhibited increased glucose tolerance topologies are illustrated schematically in Figure 3 and
with selected molecular structures in Figure 4. In theand insulin sensitivity [78]. Thus, SHIP2 appears to be
an essential negative regulator of insulin signaling and classical “recruitment” model, the DAG chains that
would be buried in the lipid bilayer are minimally involvedsensitivity, and altered SHIP2 activity may be a contrib-
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proved to be ahead of its time, was bifunctional, con-
taining both a biotinylated tag and photoactivatable de-
rivative [95] for the purpose of isolating peptide frag-
ments of InsPn binding protein active sites. Attempts to
modify the other nonphosphorylated C-6 position re-
sulted in loss of activity. The uses of these materials for
protein purifications are described below. Modifications
of positions in other InsPn regioisomers have been little
explored, with the exception of the placement of a
5-ester function in Ins(1,2,6)P3 for attachment of a photo-
affinity label that did not interfere with the activity or
binding of -trinositol [92].
Acyl-Modified Reagents
Having established a protecting group strategy for se-
lective P-1 modifications, we next prepared each of the
lipid-modified phosphoinositides shown in Figure 1. In
each case, tethered forms were prepared by using an
sn-1-O-(6-aminohexanoyl) derivative to which reporter
groups could then be attached via an amide linkage. In
this way, biotinylated [96] and fluorescent derivatives of
PI(4,5)P2 and PI(3,4,5)P3 [87], PI(3)P and PI(4)P [88],
PI(5)P and PI(3,5)P2 [89], and PI(3,4)P2 [97] were pre-
pared. Subsequently, additional syntheses of biotinyl-
ated PI(3,4,5)P3 [98, 99] and resin-immobilized PI(4,5)P2
Figure 3. Molecular Topologies of Different Tethering Modes for [100] and PI(3,4,5)P3 were described. In addition, an [125I]-
InsPn and PIPn Affinity Probes labeled dioctanoyl PI(3,4,5)P3 was employed to identify
the role of different PIPns in the activation of the Rac-
in binding; the electrostatic and hydrogen-bonding in- related GTPase Vav [101]. In this example, PI(4,5)P2 in-
teractions with the exposed, water-soluble phosphory- hibited Vav phosphorylation, while PI(3,4,5)P3 enhanced
lated inosityl head group were the dominant factors. phosphorylation and activation of Vav by the kinase Lck.
This view has changed with increased understanding of The main advantage of acyl tethering is that the re-
the importance of length and unsaturation of the DAG porter group is located in a region that is not likely to
moiety [82] and the clear identification of fatty acyl- interact with the binding site for the PIPn head group or
protein contacts in FYVE [83] and PX [32] domains. with residues near the active site that interact with the
P-1 Tethered, Soluble InsPn Reagents glyceryl ester region of the DAG moiety. While this strat-
To identify and characterize protein targets of these egy is effective for many PIPn binding proteins, three
signaling molecules, we first synthesized P-1 or P-2 main drawbacks have been noted. First, the acyl-modi-
tethered affinity probes of soluble InsPns [84–86] (Figure fied PIPns are often less hydrophobic, and the probe
4). (P-1 refers to the phosphate at the 1-position of the moiety often interferes with the insertion of the DAG
myo-inositol ring.) We adapted the Ferrier rearrange- group into a lipid bilayer. Second, modification of the
ment of differentially protected methyl -D-glucopyra- size, shape, and physicochemical properties of the DAG
nosides to provide access to all of the possible head moiety can alter the ability of the acyl-tethered PIPn to
groups present in the known PIPns [84, 87–89]. These act as a substrate or ligand. Third, when proteins dock
synthetic routes allowed introduction of affinity probes to the head group in a lipid bilayer, the reporter group
in a region of space that was generally well tolerated by may be too distant or otherwise unavailable for direct
most proteins studied. In later work, other P-1 tethered interaction with the PIPn binding protein. This has been
probes were independently prepared [90], and their af- a cause for failure in some attempted resonance energy
finity for the Ins(1,4,5)P3 receptor was analyzed by sur- transfer and photoaffinity labeling studies.
face plasmon resonance (SPR) spectroscopy. Hydropho- Ether lipids based on phosphoinositides have also
bic and charged moieties linked to this position appeared been synthesized. For example, the 3-deoxy PIPn ether
to enhance the affinity for the Ins(1,4,5)P3 receptor [91]. lipid analogs [102] were prepared as potential inhibitors
Finally, in some cases, e.g., the unnatural Ins(1,2,6)P3, of PI 3-kinase or to bind PH domains. A tritium-labeled
an experimental anti-inflammatory drug known as diundecyl ether analog of PI(4,5)P2 was prepared as
-trinositol, a different tethering regiochemistry was re- lipase-resistant tracer [103], and the 1-O-hexadecyl,
quired in order to preserve biological activity [92]. 2-O-methyl ether of PI(3,4,5)P3 was found to be a stable
Ring-Modified InsPn Derivatives and biologically active analog with low serum albumin
The Ozaki group pioneered the synthesis of Ins(1,4,5)P3 binding [98].
in which the 2-hydroxyl group was esterified to deriva- Triester-Modified Reagents
tives such as the p-azido or diazobenzoates or the To address the inaccessibility of reporter groups in the
(4-aminocyclohexyl)carboxylate. These 2-substituted acyl-modified PIPn derivatives to residues adjacent to
derivatives were used to prepare affinity matrices that the head group binding pocket and to provide further
were then employed for protein purifications [93, 94] flexibility in size and charge of the reporter group, we
designed a series of phosphotriester probes [88, 97,(Figure 4). One of these 2-substituted probes, which
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Figure 4. Chemistry of Tethered Phosphoinositide Topologies
(A) Comparison of PI(4,5)P2 molecular types attached to a resin, lipophilic BODIPY fluorophore, biotin, benzoyldihydrocinnamoyl (BZDC)
photophore, and proxyl spin label.
(B) Preparation of a PI(3,4,5)P3 PolyPIPosome by irradiation of a polymerizable liposome containing a diyne-linked Ins(1,3,4,5)P4 head group.
104]. In these derivatives, an additional P-1 phosphate the “two-headed” or hybrid phospholipid approach.
Thus, we synthesized a four-carbon threitol backbonemodification adds a pendant aminopropyl moiety in the
vicinity of the head group, while the DAG moiety is pre- with a readily derivatized phosphatidylethanolamine (PE
or Pea) headgroup at one primary hydroxyl group, a PIPnserved intact. Unlike the acyl-tethered derivatives, these
probes were specifically designed to sample the envi- head group at the other primary hydroxyl, and two acyl
chains on the internal 2,3-diol. The first synthetic hybridronment at the lipid-head group interface and to allow
normal incorporation into a lipid bilayer. The PI(4,5)P2, lipids, or Pea-PIPs, were the NBD, fluorescein, biotin,
and proxyl derivatives of the ethanolamine for Pea-PI(3,4)P2, and PI(3,4,5)P3 triester photoaffinity probes
have been used in a number of comparative labeling PI(4,5)P2 [106]. Subsequently, the technology has been
expanded to prepare each of the eight head groupsstudies, as presented below. The photolabeling of hu-
man profilin by acyl, head group, and triester probes for possible in a Pea-PIP, and additional fluorescent and
immobilized derivatives are being evaluated as biophys-the Ins(1,4,5)P3/PI(4,5)P2 head group provides a clear
example of preferential labeling [105]. Still, these probes ical and cellular probes (P.W. Rzepecki, P.O. Neilsen,
and G.D.P., unpublished results). The hybrid lipids ap-had the disadvantages of being sterically crowded near
the head group as well as perturbing the normal phos- pear to possess several characteristics that may make
them preferable to the acyl-modified PIPns: (1) Pea-PIPsphodiester linkage to the DAG moiety.
Hybrid Phospholipids have improved water solubility, (2) many Pea-PIP deriva-
tives translocate into cells and partition to cell mem-In order to address the problems of steric crowding and
to restore the normal phosphodiester linkage to the DAG branes without intracellular delivery methods developed
for acyl-modified PIPns [107], (3) Pea-PIP derivativesmoiety, we developed a novel topology, which we called
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give improved binding kinetics with PH domains, and analysis, illustrating that the originally used tethered
PIPn may not uniquely determine the lipid selectivity of(4) Pea-PIP derivatives are processed by the majority
of lipid phosphatases and kinases examined. Details on the protein captured. Below, three methods of using
InsPn and PIPn affinity matrices for purification of pro-these reagents will be presented in due course.
PolyPIPosomes teins from cell or tissue homogenates are described.
First, affinity matrices have been used in classical purifi-None of the molecular approaches above addressed the
importance of the normal bilayer environment, in which cations from tissue or cell homogenates. Second, cDNA
expression libraries have been screened with immobi-an avidity effect arises from the proximity of multiple
PIPns presenting head groups toward the cytoplasmic lized or biotinylated PIPn affinity probes. Third, a modifi-
cation of PIPn affinity supports will be described thatspace. Using PIPn-containing liposomes is a common
method for measuring ligand binding to PIPns [108, 109]; allows isolation of PIPn-complexed signaling com-
plexes.the difficulty of preparing reproducible liposomes and
the instability of the liposomes remain problematic. Classical Biochemical Isolations
from Tissues or CellsThus, we devised a method of tethering InsPn head
groups via the P-1 aminopropyl linked to the polymeriza- The first affinity purifications employed P-1 tethered
Ins(1,4,5)P3 and 2-modified Ins(1,4,5)P3 that had beenble 10,12-pentacosadiynoic acid. This surrogate PIPn
(5%) is combined with diyne-PE (29%), biotinylated- covalently linked to activated ester groups on agarose
to give amide-linked ligands with 10 A˚ tethers. Thediyne-PE (1%), and diyne-phosphatidylcholine (PC)
(65%), formed into liposomes, and crosslinked with UV P-1 tethered Ins(1,4,5)P3 resin was first employed for
purification of the Ins(1,4,5)P3 receptor from mouse cere-light (254 nm) [110] to give polymerized PIPn-containing
liposomes. Designated PolyPIPosomes, these pale red, bellar membranes [118]. Independently, the 2-modified
Ins(1,4,5)P3 affinity matrices [93, 94, 119] were employed100 nm nanoparticles are stable for many months in
buffer suspension. Preliminary results indicate that the for purification of binding proteins from rat brain mem-
branes [120], purified recombinant PH domains fromPI(4,5)P2 and PI(3,4,5)P3 PolyPIPosomes may be pre-
ferred to acyl-modified PIPns for obtaining binding kinet- PLC-1 [121], InsPn phosphatases [122], solubilized
Ins(1,4,5)P3 receptors from bovine liver microsomesics using SPR (C.G. Ferguson, R. James, Y. Abdiche,
D.G. Myszka, and G.D.P., unpublished results). [123], and a novel 130 kDa PLC 1-related protein (p130)
that bound Ins(1,4,5)P3. The p130 protein shared 38%
sequence identity with PLC-1 [124] and was essential
Protein Discovery with PIPn Affinity Probes for normal function of GABAA receptors [125].
Since the early 1990s, affinity probes for InsPns and Next, P-1 tethered Ins(1,3,4,5)P4 was used to isolate
PIPns have been used extensively to identify and charac- mouse cerebellar proteins with high affinity for either
terize InsPn and PIPn binding proteins. The specific ex- the soluble ligand or, as discovered later, for the head
amples that follow use affinity reagents for six main group of PI(3,4,5)P3 [126]. The first protein, a putative
purposes: (1) isolation and purification of binding pro- InsP6 receptor, was characterized as the -subunit of
teins, (2) domain identification and mapping of the active assembly AP-2 [127]. This same purification afforded
site, (3) biophysical measurements of binding affinity numerous other proteins, later characterized as cen-
and ligand selectivity, (4) intracellular visualization with taurin  [116], AMP deaminase [128], and GCS1 [129].
fluorescent lipids, (5) generation and use of anti-PIPn Later, the Ins(1,3,4,5)P4 affinity resin was used to isolate
antibodies, and (6) development of high-throughput -actinin from focal adhesions of PDGF-activated fibro-
screening (HTS) assays for drug discovery. In several blasts in a study of the role of PI(3,4,5)P3 in regulation
cases, direct comparisons of probes with different mo- of cell motility and adhesion [130].
lecular topologies is possible, e.g., comparing the affin- Two forms of tethered phytic acid were prepared and
ity of the Grp1 PH domain [111, 112] for P-1 aminopro- employed for purifications [85, 131]. Most purifications
pyl-linked Ins(1,3,4,5)P4 [113], acyl-modified PI(3,4,5)P3 used the P-2 tethered InsP6 [131], since by modifying
[87, 114], Pea-PI(3,4,5)P3 [106], and PI(3,4,5)P3 PolyPIPo- the axial C-2 phosphate, the achiral meso nature of InsP6
somes, as well as with noncovalently nitrocellulose- was preserved. This matrix was employed to purify an
bound dipalmitoyl-PI(3,4,5)P3 [115]. The chiral head Ins(1,3,4)P3 5/6-kinase [132] and also an InsP6-kinase
group for each of these five molecular species was pre- that produces the diphosphate PP-InsP5 (“InsP7”) [133],
pared by the Ferrier chemistry route [84, 113]. a molecule that launched a new frontier for inositol poly-
Both the types of proteins identified and the kinetics phosphate research [134]. The known protein kinase
of interactions can be influenced by the tethering chem- MAST205 could be purified using an InsP6 resin [135].
istry and the source of proteins. For example, tethered In more recent studies, affinity matrices using tethered
Ins(1,3,4,5)P4, the head group of PI(3,4,5)P3, was used PIPn derivatives have been employed. The first resin-
to isolate the novel protein centaurin- [116] from solubi- immobilized biotinylated PIPn derivatives were used for
lized mouse cerebellar membranes. In contrast, tethered in vitro expression cloning from mouse spleen [117, 136].
PI(3,4,5)P3 captured a unique 35 kDa adaptor protein In later studies, an amide-linked PI(4,5)P2 matrix was
from over 200,000 in vitro expressed polypeptides [96]. synthesized by coupling an aminoalkanoyl PIPn deriva-
Most recently, ING2, a zinc finger PHD nuclear protein tive to NHS-activated agarose [100]. This material was
involved in chromatin remodeling, was identified as a used to examine differential binding of traffic-related
weak PI(3,4,5)P3-interacting protein by expression clon- proteins to the PI(4,5)P2 matrix or to a similarly prepared
ing [117]. ING2 was subsequently found to prefer PI(5)P phosphatidic acid matrix [137]. Similarly, an amide-
linked PI(3,4,5)P3 resin was prepared and used to isolateas a ligand, as determined by SPR and PIP Array [115]
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ARAP3, a novel 170 kDa protein with five PH domains, matin remodeling family of plant homeodomain (PHD)
finger-containing proteins with a nuclear localizationfrom pig leukocyte cytosol [138]. ARAP3 regulates both
Arf and Rho GTPases and is important in cytoskeletal signal (NLS). The PHD finger consists of two interlaced
zinc binding motifs of Cys4 and HisCys3, both of whichchanges. Over 20 other known and novel proteins were
isolated from this affinity purification, including Btk, Etk, are required for proper folding in order to maintain PI(5)P
affinity. This was confirmed using a structural model ofcentaurin, Cdc42-GAP, type II inositol polyphosphate
5-phosphatase, ezrin, cytohesin-4, PHISH/DAPP1, and the ING2 PHD (computed using a FYVE domain Zn-
finger structure) followed by site targeted mutations torasGAPIP4BP. The cytosol of pig platelets, sheep brain,
sheep liver, and rat liver was also probed for proteins identify the 49-KXKXK-53 motif involved in lipid binding.
Ligand specificity was demonstrated by SPR and pro-that bound to immobilized PI(3,4P)2 (which bound vin-
culin), PI(3,5)P2 (which bound -tocopherol transfer pro- tein overlay methods. Endogenous ING2 was shown to
play a crucial role in p53-regulated apoptotic pathways,tein), and PI(3)P (which bound type C phosphofructoki-
nase) [138]. Proteins were digested with trypsin and and expression of a construct of three tandem PHD
fingers acted as a dominant negative to suppress ING2identified by mass fingerprinting and sequencing.
Finally, rat lung cell cytosolic proteins were purified function in etoposide-induced apoptosis of HT1080 cells
by sequestering PI(5)P from its normal target proteinsby PI(3,4,5)P3 affinity chromatography [139], and two
prominent protein bands were characterized by MS as in the nucleus.
Finally, a meso-P-2-aminohexyl-linked biotinylatedthe cytohesin family of Arf guanosine nucleotide ex-
change factors (cytohesin 1, ARNO, GRP-1) and Btk. InsP6 derivative [131, 143] was prepared and used to
screen a P388D1 macrophage cDNA expression library.Using the same affinity purification scheme with rat brain
homogenates, however, yielded only p42IP4, a protein MAST205 kinase, a known Ser/Thr kinase in the lipopoly-
saccharide (LPS) signaling pathway linked to NF-kB ac-identical to murine centaurin . The cytohesins in rat
brain surprisingly did not bind to the PI(3,4,5)P3-affinity tivation, was obtained from this screen [135]. The bind-
ing of MAST205 to InsP6 was attributed to a PDZ domaincolumn. Gel filtration experiments of brain cytosol re-
vealed that brain cytohesins are bound to large molecu- that is known to bind PI(4,5)P2.; InsP6 inhibited the phos-
phorylation of MAST205 [135].lar weight complexes (150 to more than 500 kDa), while
in lung cytosol, cytohesins occur as dimers. Thus, oligo- Functional Lipidomics-Proteomics Approach
Solid supports that contained immobilized biotinylatedmerization of PI(3,4,5)P3 binding proteins can modulate
their function in a tissue-dependent manner [139]. This PI(3,4)P2 and PI(3,4,5)P3 were used to capture novel pro-
teins from chemokine-activated murine macrophagescomparative approach foreshadowed the subsequent
development of a pathway-wide signaling proteomics (C. Pasquali, D. Meier, K. Mechtler, F. Vilbois, C. Chabert,
C. Arod, I. Xenarios, C. Ferguson, R. Booth, M. Camps,strategy for signalosome characterization, as discussed
below. G.D.P., and C. Rommel, submitted). Immobilized biotin-
ylated PI(4,5)P2 served as the negative control. We thenIn Vitro Expression Cloning (IVEC) Strategies
Beginning in 1996, the P-1 tethered Ins(1,3,4,5)P4 resin introduced a minor modification: the use of a disulfide-
containing linker that provided reductively cleavable af-was employed to screen mouse spleen proteins ex-
pressed from cDNAs pools using IVEC [96]. In the initial finity ligands. This modified affinity method was then
used to isolate PIPn-associated protein complexes un-screens of 1000 expressed cDNAs per tube, a dozen
high-affinity binding proteins, e.g., PDK1 and centaurin der nondenaturing conditions. Proteins of interest were
identified directly by MS/MS, and both a sensitive radio-/p42IP4, were identified using 300 mM NaCl to suppress
nonspecific binding. This screen then made the first use metric lipid-protein binding assay and an in-gel protein
kinase assay were used to evaluate signaling com-of the newly synthesized acyl-biotinyl-PI(3,4)P2 and acyl-
biotinyl-PI(3,4,5)P3 anchored to streptavidin-agarose plexes. With very limited material, potential novel lipid
binding proteins were identified, and algorithms werebeads as an affinity matrix. A novel 35 kDa protein,
PHISH, or 3-phosphoinositide-interacting src homol- used to cluster the proteins functionally as enzymes,
cytoskeletal-associated proteins, or membrane pro-ogy-containing protein [96], contained an SH2 domain,
a PH domain, and a Tyr phosphorylation motif and was teins. The mild elution conditions (DTT) from the disul-
fide-PIPn matrices allowed sensitive and selective dis-independently described from the human genome as
DAPP1 [140]. Interestingly, PHISH was also identified section of multiprotein complexes from this single cell
during the same time frame from a human leukocyte type as a function of chemokine-mediated activation of
cDNA library as SPIEL (SH2-containing 3-phosphoinosi- the PI 3-K -signaling pathway. This signaling-oriented
tide interactor expressed in leukocytes). SPIEL was proteomic approach has the potential to provide global
found using TOPIS (targets of PI3K identification sys- data on the supramolecular composition of PIPn-com-
tem), a novel assay in the yeast Saccharomyces cere- plexed signalosomes.
visiae, which used a temperature-sensitive rescue
approach based on a Ras-PH fusion that required mem-
Biophysical and Cellular Studies with InsPnbrane targeting by either PI(3,4)P2 or PI(3,4,5)P3 [141,
and PIPn Affinity Probes142]. Binding, photoaffinity labeling, and protein overlay
Photoaffinity Labeling and Peptide Mappingassays confirmed the dual specificity of PHISH for
The success of P-1 modified InsPns as affinity reagentsPI(3,4)P2 and PI(3,4,5)P3 [96].
inspired other applications for protein characterization.A protein isolated from this study was recently identi-
The first method used photoaffinity labeling with tritium-fied as a PI(5)P-selective binding protein [117]. This pro-
tein, ING2, belongs to the tumor suppressor and chro- labeled benzophenone derivatives [144, 145]. The 2,3-
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ditritio 4-benzoyldihydrocinnamoyl (BZDC) probes [146] below. First, synaptotagmin II (Syt II), a synaptic vesicle
protein involved as a mediator of exocytosis and vesiclehad proven superior to the radioiodinated azidosalicyl-
amide derivatives employed initially, e.g., for the peptide recycling, contains two phospholipid binding C2A and
C2B domains. The former acts as a Ca2 sensor, whilemapping of the affinity–purified Ins(1,4,5)P3 receptor
[118]. In general, photolabeling with BZDC-PIPns pro- the latter binds inositol polyphosphates. Photoaffinity
analogs of Ins(1,4,5)P3, Ins(1,3,4,5)P4, and InsP6 thatvided three types of biological information: (1) identifica-
tion of PIP binding proteins in mixtures, (2) relative affini- contained the BZDC photophore were used to label
GST fusion proteins of the Syt II-C2A and C2B domainsties of different PIPns for a given protein, and (3)
localization of the PIPn binding site(s). [153]. The rank order of photocovalent modification par-
alleled the order of competitive displacement: InsP6After purification of mouse brain proteins on an
Ins(1,3,4,5)P4 resin, photoaffinity labeling [126, 147, 148] (P-2-linked)  Ins(1,3,4,5)P4  Ins(1,4,5)P3.
Second, clathrin coating of vesicles during endocyto-was used to confirm PIPn affinity and specificity. Cen-
taurin /p42IP4 (now centaurin 1) [116], the first member sis is regulated by InsPn and PIPn-mediated assembly
proteins AP-2 [154] and AP-3 (aka, AP-180) [155]. AP-2of centaurin family of PI(3,4,5)P3 binding proteins [149],
was identified using this approach. Rat adipocyte cen- was isolated by affinity purification and photoaffinity
labeling with Ins(1,3,4,5)P4 affinity reagents [127]. Usingtaurin 2, a membrane protein with two PH domains,
was 51% identical to centaurin ı and abundantly ex- a palette of PIPn photoprobes, the  subunit of AP-2
was labeled [156]. In a closely related project, a solublepressed in fat, heart, and skeletal muscle. Photoaffin-
ity labeling with [3H]-BZDC-PI(3,4,5)P3 and [3H]-BZDC- BZDC-Ins(1,3,4,5)P4 analog was used to label the N-ter-
minal third of AP-180 [157], known to contain the PIPnPI(3,4)P2 probes confirmed the different ligand specific-
ity for two isoforms [150]. Three other proteins were also binding site [155]. This region was later identified as the
ENTH domain [24].obtained from this purification: AMP deaminase [128],
GCS1 [129], and synaptotagmin. AMP deaminase is a Third, profilin binds actin monomers, poly(L-proline),
and PIPns and regulates actin filament dynamics that aretightly regulated brain enzyme in the adenylate pathway.
Endogenous (rat) and recombinant human AMP deami- essential for cell motility. Human profilin I was covalently
modified using three [3H]BZDC-containing photoaffin-nase specifically bound PI(4,5)P2 in both photolabeling
and liposome binding assays, and this binding could ity analogs of PtdIns(4,5,)P2 [105]. The P-1-tethered
Ins(1,4,5)P3 analog showed efficient and specific photo-regulate localization and enzymatic activity in vivo [128].
GCS1, the mouse homolog of a yeast protein with ARF- covalent modification of profilin I, which was competi-
tively displaceable by PI(4,5)P2 analogs but not byGAP activity, is required in vivo for normal actin cyto-
skeletal organization [129]. The yeast homolog GCS1p Ins(1,4,5)P3. In contrast, the BZDC-acyl-PI(4,5)P2 showed
little protein labeling, while the BZDC-triester-PI(4,5)P2was cloned, expressed, and photoaffinity labeled with
[3H]-BZDC-Ins(1,3,4,5)P4 and [3H]-BZDC-PI(3,4,5)P3 labeled both monomeric and oligomeric profilin I.
[3H]BZDC-Ins(1,4,5)P3-labeled profilin I labeled the N-ter-probes [129].
A 4-(BZDC)-aminopentanoyl-linked Ins(1,2,6)P3 de- minal 13 amino acid fragment, and the covalent modifi-
cation of Ala-1 of profilin I was confirmed by Edmanrivative as well as a P-5-(BZDC-aminopropyl) linked
Ins(1,2,5,6)P4 derivative were used to search for putative degradation. The PI(4,5,)P2 binding site includes a bis-
phosphate interaction with a base-rich motif in the-trinositol receptors in human umbilical cord vascular
smooth muscle cells and platelet membranes [92]. Only C-terminal helix and contact between the lipid moiety
of PI(4,5,)P2 with a hydrophobic inner patch of thethe 4-linked ester probe showed specific labeling of
43 and 55 kDa proteins, with Ins(1,2,6)P3 but not N-terminal helix of profilin.
Fourth, photoaffinity labeling of three constructs—Ins(1,3,4,5)P4 showing competitive displacement of the
binding. Unfortunately, these potential molecular tar- full-length, N-terminal, and C-terminal halves—of re-
combinant human plasma gelsolin was performed withgets for this novel antivasoconstrictive drug remain un-
confirmed and have not yet been identified. four different acyl- and triester-[3H]BZDC-PIPn probes
[158]. Specificity was demonstrated by displacementThe PH domain but not the catalytic site of PLC 1
isoform was efficiently photolabeled with [3H]BZDC- with various short-chain PIPn analogs. In addition to the
known PI(4,5)P2 binding site in the N-terminal half, weIns(1,4,5)P3. The presence of high-affinity PI(4,5)P2 and
PI(3,4,5)P3 binding sites in PLC 1, 1, 2, and 3 iso- located a novel PIPn binding site on the C-terminal half
of gelsolin that required the intact protein. Proteolysis,zymes was probed with photolabile BZDC analogs of
Ins(1,4,5)P3, Ins(1,3,4,5)P4, InsP6, PI(4,5)P2, and PI(3,4,5) purification, and sequencing led to the identification of
the labeled region in residues 621–634 [158].P3 [19]. Only PLC 1 was specifically labeled, with a
single, high-affinity binding site found in the PLC 1 PH Fifth, coatomer, a complex of seven coat proteins
(COPs) involved in the formation of specific Golgi inter-domain. No photolabeling of the 1, 2, and 3 isoforms
was detected. Binding was also probed in recombinant cisternal transport vesicles, binds Ins(1,3,4,5)P4 and
InsP6 with subnanomolar affinity [159]. Phosphoinositidehuman phospholipase D2 (PLD2), which requires PI(4,5)
P2 for activation. Photoaffinity labeling with both acyl- and subunit selectivity were examined using P-1-linked
photoaffinity analogs of the soluble inositol polyphos-[3H]-BZDC-PI(4,5)P2 and triester-[3H]-BZDC-PI(4,5)P2 re-
vealed displacement by PI(4,5)P2 but not by PI or PI(4)P phates Ins(1,4,5)P3 and Ins(1,3,4,5)P4, a P-2-linked ana-
log of InsP6, and P-1-linked phosphotriester analogs[21] [151].
A number of proteins involved in PIPn-regulated vesic- of the polyphosphoinositides PI(3,4,5)P3, PI(4,5)P2, and
PI(3,4)P2. Labeling of the Golgi coatomer COPI complexular trafficking [152] have been studied with BZDC-
labeled InsPn and PIPns, and several will be described showed a highly selective Ins(1,3,4,5)P4-displaceable
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photocovalent modification of the COP subunit by fied by linking P-1 aminopropyl Ins(1,4,5)P3, Ins(1,3,4,5)
P4, or InsP6 to NHS/carbodiimide-activated carboxy-[3H]BZDC-Ins(1,3,4,5)P4 probe, while the P-2-linked
[3H]BZDC-InsP6 probe labeled six of the seven subunits. methyldextran. C2B and C2AC2B domains had the
highest affinity for the Ins(1,3,4,5)P4 modified surface,Most importantly, [3H]BZDC-triester-PI(3,4,5)P3, the poly-
phosphoinositide analog with the same phosphorylation and the short-chain analogs of PI(4,5)P2 and PI(3,4,5)P3
were more effective than head groups in displacingpattern as Ins(1,3,4,5)P4, also showed completely spe-
cific, PI(3,4,5)P3-displaceable labeling of COP [160]. In binding, suggesting that the SytII C2B domains use PIPn
interactions in docking and/or fusion of the secretorycontrast, labeling by BZDC-PI(4,5)P2 and BZDC-PI(3,4)
P2 showed no discrimination based on the PIPn ligand. vesicles to the synaptic membrane.
Most recently, experiments have used BIAcore 2000These data suggest the critical importance of the D-3
and D-5 phosphates in regulation of the recruitment of with CM5 sensor chips to compare acyl-linked PIPns
with the new Pea-PIP and PolyPIPosome architecturesmembranes during vesicle budding in signal transduc-
tion and thus implicate PI 3-K in this process [160]. for use in determining on-rates and off-rates for PH
domain-PIPn interactions (C.G. Ferguson, P.W. Rzep-Finally, three brief collaborative studies are illustrative
of the scope of the photolabeling approach. In one ex- ecki, P.O. Neilsen, Y. Abdiche, D.G. Myszka, and G.D.P.,
unpublished results). Streptavidin was immobilized toample, PITP, a putative transfer protein for phosphati-
dylinositol, was labeled with triester [3H]-BZDC analogs the chips and used to capture three biotinylated
PI(3,4,5)P3 probes [acyl-biotinylated PI(3,4,5)P3, biotinyl-of PI(4,5)P2 and PI(3,4,5)P3, and competitive displace-
ment was only observed using PI(3,4,5)P3. This sup- ated Pea-PI(3,4,5)P3, and biotinylated PI(3,4,5)P3 PolyPI-
Posome]. The binding of the highly PI(3,4,5)P3-selectiveported a role for PITP as a scavenger of PI(3,4,5)P3 in
stimulating the activity of PI 3-K [161]. In a second Grp1-PH domain [111, 112] was analyzed in a glycerol
and serum albumin-containing buffer at pH 7.4. Rapidcollaboration, acyl-[3H]-BZDC-PI(4,5)P2 and [3H]-BZDC-
Ins(1,4,5)P3 were used to label the holoprotein and the flow rates minimized the effects of mass-transport limi-
tations. Estimates of Grp1 binding affinity revealed thatPH domain of the yeast oxysterol binding protein homo-
log Kes1p. Labeling was specifically displaced by biotinylated Pea-PI(3,4,5)P3 and biotinylated PI(3,4,5)P3
PolyPIPosome surfaces were equivalent (KD  2.4 nM),PI(4,5)P2 but not by other phospholipids, PIPns, or solu-
ble InsPns [162]. Finally, an unusual tripartite interaction while Grp1 bound acyl-biotinylated PI(3,4,5)P3 with a
5-fold lower affinity (KD  12 nM). This suggested thatbetween the transmembrane heparan sulfate proteogly-
can syndecan-4, the lipid PI(4,5)P2, and protein kinase the presentations of the PI(3,4,5)P3 head group in the
two-headed lipid and polymerized liposome were supe-C was investigated. The PI(4,5)P2-syndecan-4 interac-
tion resulted in syndecan-4 oligomerization, an effect rior to that of the acyl-modified lipid.
Anti-PIPn Antibodiesthat was competable by InsP6 but not by Ins(1,3,4,5)P4.
The region of the protein responsible for this regulation A method other than GFP-PH domains [167] was re-
quired to visualize specific PIPns in a number of cellularwas identified by photoaffinity labeling with [3H]-BZDC-
Ins(1,3,4,5)P4 and [3H]-BZDC-InsP6 [163]. compartments. Although small lipids are in general
poorly antigenic, liposomal preparations and bioconju-Spectroscopic Studies with Spin-Labeled PIPns
The first spin-labeled PIPn derivatives had proxyl groups gates of PIPns have allowed production of biologically
useful anti-PIPn reagents. Monoclonal antibodies (mAbs)attached to the acyl chain, while more recent spin-
labeled Pea-PIPs [106] place the small, hydrophilic ni- against PI(4,5)P2 were first developed over 15 years ago
[168], and newer antibodies prepared against differenttroxyl-containing group closer to the protein and near
the aqueous interface occupied by the head group. Us- immunogenic forms in the past four years [169, 170].
These antisera, prepared against liposomal PI(4,5)P2,ing ESR, acyl-proxyl-PI(4,5)P2 was sequestered into lat-
eral two-dimensional domains by the MARCKS polyba- colocalized PI(4,5)P2 with splicing factor SC-35, a known
marker for nuclear speckles, implicating PI(4,5)P2 in thesic peptide [164]. An analogous study with the SCAMP
peptide compared acyl-proxyl PI(4,5)P2 with proxyl-Pea- assembly of a mitotically regulated particle important in
pre-mRNA splicing [43]. Moreover, PI(4,5)P2 was com-PI(4,5)P2, in which the spin label interacts not with the
lipid bilayer but with the peptide head group. The proxyl pletely colocalized with SC-35 and partially colocalized
with DAG kinase  in MB-453, MCF-7, PC-12, and HeLaspin label in the Pea-PIP is in a completely aqueous
environment and produces a greater signal than the cells [44]. The nuclear PI(4,5)P2 staining seen in normal
mouse fibroblasts was absent in cells expressing theacyl-linked proxyl group (D. Cafiso, D. Castle, P.W.
Rzepecki, and G.D.P., unpublished results). Similarly, in beige gene orthologous to the human Chediak-Higashi
Syndrome gene [49].NMR studies of paramagnetic line broadening due to the
interaction of acyl-proxyl PI(3)P with the FYVE domain, When liposomes containing synthetic dipalmitoyl
PI(3,4,5)P3 were unsuccessful in eliciting an immune re-Kutataladze and coworkers established the angle of bi-
layer insertion and identified hydrophobic residues in a sponse, a bioconjugate was prepared by coupling over
100 succinyl-modified PI(3,4,5)P3 molecules to the Lysloop that interacted with the lipid tails of PI(3)P [165].
Surface-Immobilized PIPns in SPR residues of keyhole limpet hemocyanin (KLH) (Figure
5A). This immunogenic form of PI(3,4,5)P3 was employedThe binding kinetics and ligand specificity for the inter-
actions of a series of IPn and PIPn species with the C2B to obtain the first anti-PI(3,4,5)P3 mAbs [171]; PIPn selec-
tivity was demonstrated by photoaffinity labeling anddomain of synaptotagmin II (Syt II) was measured using
SPR [166]. The on- and off-rates of His-tagged SytII- ELISA. Moreover, stimulation of neutrophils with fMLP
led to a rapid (7 s) and transient peak of immunoreactiveC2B (and C2B  C2A) were determined on BIAcore
Pioneer B1 sensor chips that had been covalently modi- PI(3,4,5)P3, while activation of NIH 3T3 fibroblasts with
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Figure 5. Immunodetection of Phosphoinositides
KLH, keyhole limpet hemocyanin; EDCI, ethyl N,N-dimethylaminopropylcarbodiimide.
(A) Preparation of an antigenic PI(3,4,5)P3 bioconjugate.
(B) Visualization of PI(3,4,5)P3 in stimulated fibroblasts [171].
PDGF showed maximal PI(3,4,5)P3 in cytoplasmic com- observed (B.E. Drees, S. Dhardmawardhane, G.B. Mills,
and G.D.P., unpublished results).partments after 5–10 min with a slower return to baseline
levels (Figure 5B). Interestingly, from 15–30 min, a peak In a related approach, polyclonal antibodies against
Ins(1,4,5)P3 were raised by immunizing rabbits with P-1-of PI(4,5)P2 production was observed in the nucleus. The
anti-PI(3,4,5)P3 IgMs have also been used to visualize tethered Ins(1,4,5)P3-BSA conjugates [174]. An ELISA
using immobilized Ins(1,4,5)P3 as the capture antigenspatiotemporal changes in PI(3,4,5)P3 in bovine aortic
endothelial cells (BAECs) in culture and hepatocytes of showed sensitivity and selectivity: while most InsPns and
PtdIns(4,5)P2 did not compete for binding, Ins(1,3,4,5)P4intact rat liver [172]. Treatment of the BAECs with either
insulin or leptin increased PI(3,4,5)P3, and this could be had 33% of the affinity of Ins(1,4,5)P3. The affinity-puri-
fied antibody displayed IC50 values of 12 nM forblocked with PI 3-K inhibitors [172]. Moreover, immuno-
histochemistry also showed preferentially increased Ins(1,4,5)P3. Follow-up studies using this antibody in
biological contexts remain unreported. Because InsPnsPI(3,4,5)P3 in cells of the acuate nucleus of the hypothal-
amus that contained insulin receptor substrate (IRS)-2, are water soluble, are highly metabolically labile in vivo,
and are not localized to membranes, the applicationsproviding a mechanism for neuronal crosstalk between
insulin and leptin signaling pathways [173]. of anti-InsPn mAbs in cell biology have appeared limited.
Nonetheless, potential applications in metabolite analy-In many types of cancer, upregulation of PI 3-K activity
and abrogation of PTEN would be predicted to cause sis and in drug discovery suggest that efforts to obtain
additional anti-InsPn mAbs could provide useful newan overabundance of PI(3,4,5)P3 in affected tissues [4].
Indeed, staining of uterine tissues from a hysterectomy reagents.
Fluorescent PIPns in Biochemicalshowed massive amounts of PI(3,4,5)P3 immunostaining
in the metastatic side of the uterine wall but negligible and Biophysical Studies
The acyl-linked fluorescent PIPns were first developedstaining in the unaffected contralateral side [57]. Similar
results in breast cells and in ovarian tumors have been as probes in model systems and for in vitro studies of
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lipid binding proteins. The first use of NBD-PI(4,5)P2 Intracellular NBD-PI(4,5)P2 was stable for at least 30 min
in unstimulated cells, but was metabolized to NBD-DAGwas to study the role of the MARCKS polypeptide in
sequestration of PI(4,5)P2 in two-dimensional lateral and Ins(1,4,5)P3 upon stimulation with PDGF, insulin, or
bradykinin.arrays [175]. In a lipid bilayer system, acrylodan-labeled
MARCKS polypeptide colocalized with NBD-PI(4,5)P2. Chromophore-Assisted Laser Inactivation (CALI)
Laser inactivation studies with Ins(1,4,5)P3-malachiteSeparately, the inhibition of PLC hydrolysis of PI(4,5)P2
by MARCKS polypeptide was determined. Taken to- green using CALI allows the study of in situ protein
function by selective destruction of a target protein withgether, the results implicated the regulation of PLC ac-
tivity by lipid clustering and sequestration by the high spatial and temporal resolution [178]. In particular,
P-1 linked malachite green-Ins(1,4,5)P3 was used to tar-MARCKS polypeptide.
A second application of acyl-linked fluorescent PIPns get the Ins(1,4,5)P3 receptor (IP3R) using permeabilized
smooth muscle cells. When the cells were treated withexamined the effects of the PI(4,5)P2-regulated proteins
gelsolin, tau, cofilin, and profiln by using fluorescent malachite green-Ins(1,4,5)P3 followed by laser irradia-
tion, the Ins(1,4,5)P3-induced Ca2 release rate was de-PI(4,5)P2 analogs in micellar or liposomal form (with PC)
[176]. Gelsolin was unique in increasing the fluorescence creased in a concentration- and irradiation time-depen-
dent manner. Similarly, the IP3R was inactivated withof both NBD- and pyrene-PI(4,5)P2 in both systems in a
dose-dependent manner. Based on fluorescence reso- high spatiotemporal resolution in single B lymphoma
cells and in a spatially distinct region of differentiatednance energy transfer (FRET) data, it appeared that
PI(4,5)P2 bound to a site formed by the juxtaposition of PC12 cells [179].
Finally, P-1 linked BODIPY-Ins(1,4,5)P3 was used tothe N- and C-terminal domains. This corroborated the
photoaffinity labeling results, in which a new PI(4,5)P2 examine the localization and function of Ca2 stores in
isolated chromaffin cells of rat adrenal medulla usingbinding site was observed by photoaffinity labeling of
the full-length gelsolin protein [158]. confocal laser microscopy. Binding sites for BODIPY-
Ins(1,4,5)P3 were perinuclear, particularly the endoplas-The most recent applications of fluorescent PIPns and
fluorescent InsPns have been in the visualization of sub- mic reticulum, and at the cell periphery [180].
cellular distribution of exogenously administered PIPns,
and in the development of rapid HTS assays for detec-
Drug Discovery and Target Validationtion of changes in PIPn phosphorylation or levels. These
HTS Assaysapplications are described in more detail below.
Until very recently, all PI 3-K activity was determined byIntracellular Delivery of Fluorescent PIPns
using tedious radiometric endpoint assays that reliedWe sought a method for intracellular delivery of PIPns
on the biochemical conversion of PI to PI(3)P or ofthat would not require photolytic uncaging of phosphate
PI(4,5)P2 to the corresponding PI(3,4,5)P3 using 32P-ATPesters and enzymatic hydrolysis of masked hydroxyl
as the cosubstrate. After the reaction, phosphorylatedgroups [177]. We discovered that neomycin, histone
lipids were separated by thin layer chromatography andH-1, and their fluorescent derivatives could deliver IPn
quantified by liquid scintillation counting or phosphorim-(n  3,4) and PIPn (n  1,2,3) compounds into cells
aging. A 96-well format version of this PI 3-K assay[107]. Fluorescent NBD-PI(4,5)P2 was shuttled into plant
was recently described [181]. The discovery and cellular(A. thaliana) root tip cells, mammalian cells (MDCK kid-
validation of the next generation of PI 3-K inhibitoryney cells, CHO ovary cells, and NIH 3T3 fibroblasts),
compounds has been significantly accelerated by ad-bacteria (E. coli), protists (Cryptosporidium parvum),
vances in two areas: (1) the development of HTS-com-and yeast (S. cerevisiae) in the presence but not absence
patible nonradioactive assays and (2) the availabilityof a stoichiometric amount of carrier. In mammalian
of additional techniques to visualize the localizationcells, shuttled NBD-PI(4,5)P2 was localized to the plasma
and effects of differentially phosphorylated lipids inmembrane, punctate cytoplasmic structures, and nu-
cells [57].clear speckles, while shuttled NBD-PI(3,4,5)P3 localized
Several formats have now been reported for nonradio-to the plasma membrane and cytoplasmic vesicular struc-
active PI 3-K assays in 96- or 384-well formats [114,tures but remained outside of the nucleus. Histone-deliv-
182], including ELISA, ALPHAscreen, and fluorescenceered PI(4,5)P2 induced intracellular calcium mobilization in
polarization (FP) technologies, for which a variety of3T3-L1 and NIH3T3 cells, while histone-shuttled BODIPY-
patents are currently pending. As illustrated in FigurePI(3,4)P2 localized to the plasma membrane extensions in
7A, these assays employ synthetic PIPns (or InsPns) la-the same cells (see Figure 6).
beled in the acyl chain with fluorophores (for FP) orUsing the panel of small-molecule and histone-based
biotin (for ALPHAScreen; not shown) [114]. Using thesetranslocases, we explored the parameters for optimal
assays offers the possibility of accelerating the discov-intracellular delivery of PI(4,5)P2, PI(3,4)P2, and PI(3,4,5)
ery of new inhibitors of PI 3-K, a selection of whichP3 using fluorescently labeled lipids. The kinetics of up-
are illustrated in Figure 7B and reviewed in more detailtake, the localization of specific PIPns, and their meta-
elsewhere [50].bolic stability in fibroblasts, CHO, and MDCK cells have
Physiological Activity of Exogenous PIPnsnow been determined (D. DeWald, S. Ozaki, S. Malaviya,
Exogenous anionic PIPn ligands can be delivered (“shut-J. Shope, K. Manabe, L. Crosby, P. Neilsen, D. Johnston,
tled”) across the membranes of living cells using specificand G.D.P., submitted). Specifically, dendrimer-shuttled
polyamines as carriers [107]. The process occurs withinPIPns appeared to enter through focal contacts, while
a few minutes, even at reduced temperatures or in theother polycationic carriers caused uptake with entry first
evident at 20 s and generally complete within 5 min. presence of an endocytotic blocker. Moreover, fluores-
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Figure 6. Confocal Images Illustrating the Uptake of NBD-PI(3,4)P2 and Texas Red Histone in NIH 3T3 Fibroblasts Using Intracellular Delivery
Methods
(A) Sequential optical z-sections (0.2 	m) were collected 5 min after addition of PI(3,4)P2-histone complex. The montage shows six successive
1.5 	m steps from the top of the cell (1) to the attachment of the cell to the substratum (6).
(B) Pseudo-three-dimensional reconstruction. Images are courtesy of J. Shope and D.B. DeWald [107].
cently labeled PIPn ligands could be shuttled into cells supply. Fifth, exogenous PI(3)P was shown to induce
plasma membrane translocation of the glucose trans-using fluorescently tagged histone or neomycin. La-
beled PIPns were observed in the nuclei and intracellular porter protein GLUT4, a PI 3-K-dependent process oc-
curring downstream of activation of the insulin receptormembranes, an observation now consistent with the use
of newer fluorescent protein conjugates and anti-lipid [186]. Finally, the delivery of BODIPY-TR-PI(5)P to
Balb-C 3T3 cells resulted in subnuclear localization ofantibody histochemistry [57, 171]. Although we demon-
strated that both shuttled Ins(1,4,5)P3 and PI(4,5)P2 could this lipid but not BODIPY-TR-PI(3)P. Importantly, exoge-
nous PI(5)P ultimately colocalized and modulated theelicit calcium transients in living cells within 2–4 min, it
was questioned whether shuttle-delivered exogenous nuclear localization of the PHD zinc finger-containing
protein ING2 and altered chromatin remodeling in thesePIPns would have general utility in manipulating cellular
physiology. This has now been answered in the affirma- cells. ING2 binding to PI(5)P but not to PI(4)P caused
ING2 to translocate from the chromatin to the nucleo-tive by a number of studies.
First, exogenous PI(3,4)P2 was employed to restore plasm (O. Gozani, S. Field, C. Ferguson, C. Mahlke, L.
Cantley, G.D.P., and J. Yuan, submitted). Since therefull activation of Akt during steel-factor stimulation of
bone marrow-derived mast cells obtained from mice are over 100 nuclear proteins that contain PHD fingers,
additional roles of PIPn in transcriptional regulation maygenetically lacking the inositol 5-phosphatase SHIP
[183]. Other shuttled PIPn ligands were ineffective, and emerge in the future.
Manipulation of PIPn Signaling in Cellsthus both PI(3,4)P2 and PI(3,4,5)P3 were required for full
phosphorylation of Ser473 and Thr308 of Akt in SHIP The chemical rescue of PIPn function in cells described
above is the inverse of the more common pharmacologi-null cells. Second, addition of exogenous PI(3,4,5)P3 ac-
tivated a PI 3-K- and Rho GTPase-mediated positive cal approaches that employ small molecule inhibitors,
dominant negatives, cells from transgenic knockout ani-feedback loop that regulates polarization and migration
of neutrophils [10]. Remarkably, within 3 min neutrophils mals, and more recently RNA interference to reduce the
function of a given protein. Such approaches have ofbegan migrating when a histone-PI(3,4,5)P3 complex
was added to the medium; shuttling in PI(4,5)P2 or omis- course been the mainstay of studies of PI 3-K signaling,
but sadly only two low-selectivity PI 3-K inhibitors (seesion of the carrier failed to activate polarization and
migration. Third, in examining the role of InsP6 in pre- Figure 7B) have been available for the past ten years, as
recently reviewed [49, 50]. There is widespread concernventing tumor cell growth, coapplication of InsP6 with
histone induced apoptosis at a 10-fold lower dose than that many cell-based studies using LY294002 and wort-
mannin may require reinvestigation with isoform-selec-InsP6 [184]. Induction occurred by inhibition of the Akt
cell survival pathway. Fourth, in elegant work by the tive inhibitors such as the published PI 3-K inhibitor
and the as yet commercially unavailable PI 3-K , , andYin group [185], intracellular delivery of PI(4)P but not
PI(4,5)P2 rescued the phenotype of cells in which RNA  inhibitors [50, 51].
An active area of drug discovery is the identificationinterference had knocked down the resident Golgi PI
4-K required for production of the endogenous PI(4)P of Akt/PKB inhibitors using two main approaches. First,
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Figure 7. Drug Discovery in the PI 3-K Pathway
(A) Fluorescence polarization assay for PI 3-K [114].
(B) Selected inhibitors for PI 3-K [50].
(C) Akt PH domain antagonists [56].
traditional protein kinase inhibitors have become ex- fied inositol ether lipid phosphates and a carbonate (Fig-
ure 7C) were synthesized and found to inhibit both PItremely important new cancer therapeutics [187]. Thus,
an inhibitor could be targeted to the kinase domain 3-K and Akt and to slow cancer cell growth [191, 192].
These and other D-3-deoxy-phosphatidyl-myo-inositolphosphoryl transfer site of Akt, e.g., a heterocycle that
would bind with high affinity and selectivity in the ATP analogs appear to specifically inhibit membrane translo-
cation via the Akt1 PH domain [193], thereby blockingpocket. An “Aktstatin” was rationally redesigned based
on a PKA inhibitor with a modest potency and selectivity Akt activation and inhibiting its prosurvival effect in cells
[56]. This selective Akt inhibitor also reduces resistancefor Akt [188]. Second, although untested in therapy, se-
lective antagonists of PH domains would be potential to chemotherapeutic drugs and ionizing radiation in hu-
man leukemia cells [194]. The alkylphospholipid analogsmall molecule drugs. An Akt antagonist that “mimics”
PI(3,4,5)P3 could block signalosome assembly and thus perifosine (Figure 7C), an orally bioavailable drug, has
shown activity in vitro and in vivo in human tumor modelactivation of Akt by phosphorylation by PDK1 and an
as yet unknown kinase with “PDK2” activity. Indeed, systems and has entered phase I clinical trials. In PC-3
prostate cancer cells, perifosine does not inhibit PI 3-KPDK1 inhibitors (or PDK1 PH domain antagonists) could
also be potential targets for downregulation of Akt acti- but instead perturbs membrane translocation of Akt and
other PH domain-containing proteins in the PI 3-K/Aktvation. A preliminary validation of this was accomplished
by using antisense oligonucleotides to reduce the level pathway [195].
There is a need for selective inhibitors of the 3-phos-of PDK1 in cancer cells, resulting in increased apopto-
sis [189]. phatase PTEN and the 5-phosphatase SHIP in order to
study responses of coupled PI 3-K signaling pathwayIn the Akt pathway, the Kozikowski group has used
molecular modeling to predict the differential affinity of components in cells and in animals. At present, no such
selective inhibitors are commercially available. This is3-phosphorylated PIPns and to provide a structural basis
for the design of novel, high-affinity ligands that could another area where both substrate-based design and
pharmaceutical discovery of drug-like molecules is pro-modulate signaling by Akt [190]. For example, 3-modi-
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